Launching new clinical trials is a painstaking process between research sites and pharmaceutical sponsors. Novartis and IQVIA study start-up and technology experts share their multi-faceted approaches to overcome the headwinds that are slowing site activation.
In recent years, the average time between protocol approval and the first patient visit has increased dramatically, yet speed-to-market is more important than ever. Are there any effective strategies to reverse this trend of ballooning study start-up timelines?
As protocols and studies become more complex, companies are looking for comprehensive solutions that mitigate the driving forces behind delayed study launches without burdening sites with disconnected technologies.
IQVIA One Home for Sites serves as a neutral aggregator, connector, and communicator of the key systems and tasks a clinical research site needs to perform across all the trials it is conducting. See how to join this industry movement.
One Home for Sites is a new platform from IQVIA Technologies, endorsed by IQVIA Research & Development Solutions (RDS). As an aggregator of clinical trial applications, it does not compete with individual products and platforms.
Understand why companies are standardizing operations on a purpose-built, proven platform that empowers sites to succeed and provides sponsors with insights to improve performance and compliance.
